Infectious Disease & Vaccines
Persistence and determination are our mantras in the face of bacterial, fungal and viral infections—together accounting for significant threats to public health and rising healthcare costs. We are leaders in this area of research, relentlessly exploring the role of biologics, small molecules and vaccines to address these challenges.
Precise Medicine for Infection
Decades of broad antibiotic therapy has lead to widespread drug-resistant bacterial infections, disrupting the microbiome and increasing the risk for chronic disease. Precision medicines are essential for addresing the proliferation of drug resistance. We are at the forefront of this approach, developing novel therapies that prevent and treat resistant bacterial infections.
The young, the elderly and people with underlying health issues are especially susceptible to viral respiratory infections. The use of antibiotics to prevent secondary bacterial infections in these patients exacerbates the growing problem of antibacterial drug resistance. Our investigations focus on preventing--and even treating--these viral respiratory infections, particularly for high-risk patients.
The challenge for therapeutic vaccines is to generate new and potent immune responses in the face of immune exhaustion induced by chronic exposure to tumors or viral antigens. We're using nucleic acid and viral expression platforms to deliver tumor and viral antigens to the host immune system. Our goal is to drive a potent immune response against tumors and chronically infected cells.
Four years ago, the European Commission called for “unprecedented collaborative research and development efforts to bring new antibiotics to patients.” This included the launch of the sixth Innovative Medicines Initiative (IMI) Call for Proposals in 2012 as part of a program titled New Drugs 4 Bad Bugs, or ND4BB. Less than a year later, the COMBACTE consortium, an unparalleled public-private partnership that includes academia and industry, was formed.
Infectious Disease News
Infectious Disease Publications
Characterization of a Prefusion-Specific Antibody that Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database
Join us at MedImmune
Our Great Place to Work strategic initiative offers a dynamic environment that fosters collaboration and innovation. We attract top minds, and we do what it takes to nurture and build talent.